Co‐administration of the prostaglandin F2α receptor antagonist pre‐term labour drug candidate OBE022 with magnesium sulfate, atosiban, nifedipine and betamethasone

Oliver Pohl, Line Marchand, Jean‐Pierre Gotteland, Simon Coates, Jörg Täubel, Ulrike Lorch

Pohl, O, Marchand, L, Gotteland, J‐P, Coates, S, Täubel, J, Lorch, U. Coadministration of the prostaglandin F2α receptor antagonist preterm labour drug candidate OBE022 with magnesium sulfate, atosiban, nifedipine and betamethasone. Br J Clin Pharmacol. 2019; 85: 1516– 1527.https://doi.org/10.1111/bcp.13925

Safety and Pharmacokinetics of the Oral Prostaglandin F2alpha Receptor Antagonist, OBE022, in Patients With Threatened Spontaneous Preterm Labor

Andrew Humberstone, Jose Luis Bartha, Seppo Heinonen, Juha Räsänen, Aydin Tekay, Michel Brethous, Jean-Pierre Gotteland, Oliver Pohl, Ernest Loumaye

SRI Conference, 12-16 March 2019, Paris, France
Abstract S-001: page 299A

Abstracts. Reprod. Sci. 26, A62–A390 (2019). https://doi.org/10.1177/1933719119834079

Are you sure you want to leave ObsEva.com?

We’re sorry to see you go. Choose one of the following actions to stay on the site or leave.

Continue to link

Disclaimer

Note that the following information contains information on investigational medicinal products. These products have not yet been approved for marketing by the European Medicines Agency or the U.S. Food and Drug Administration and are still under development. Further additional investigations may be needed in order for the marketing authorization to be granted, which grant may depend on a variety of factors and is not guaranteed. Click on “return” if you do not wish to receive such information. By clicking on “continue” you acknowledge that you wish to receive scientific information on our investigational products.

Continue

Disclaimer

Note that the following information contains information on investigational medicinal products. These products have not yet been approved for marketing by the European Medicines Agency or the U.S. Food and Drug Administration and are still under development. Further additional investigations may be needed in order for the marketing authorization to be granted, which grant may depend on a variety of factors and is not guaranteed. Click on “return” if you do not wish to receive such information. By clicking on “continue” you acknowledge that you wish to receive scientific information on our investigational products.

Continue